These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 11885838)

  • 21. [Urothelial cancers from Endoxan].
    Dumas JP; Roulet B; Colombeau P; Loubet R
    J Urol (Paris); 1984; 90(6):411-2. PubMed ID: 6520414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; de Ramon Garrido E; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Arthritis Rheum; 2004 Dec; 50(12):3934-40. PubMed ID: 15593207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis.
    Plotz PH; Klippel JH; Decker JL; Grauman D; Wolff B; Brown BC; Rutt G
    Ann Intern Med; 1979 Aug; 91(2):221-3. PubMed ID: 464465
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence for cyclophosphamide-induced transitional cell carcinoma in a renal transplant patient.
    Tuttle TM; Williams GM; Marshall FF
    J Urol; 1988 Nov; 140(5):1009-11. PubMed ID: 3050150
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bladder leiomyosarcoma following cyclophosphamide therapy for lupus nephritis.
    Thrasher JB; Miller GJ; Wettlaufer JN
    J Urol; 1990 Jan; 143(1):119-21. PubMed ID: 2294239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclophosphamide treatment of systemic lupus erythematosus: risk of bladder cancer exceeds benefit.
    Elliott RW; Essenhigh DM; Morley AR
    Br Med J (Clin Res Ed); 1982 Apr; 284(6323):1160-1. PubMed ID: 6803878
    [No Abstract]   [Full Text] [Related]  

  • 27. Bladder malignancy in a patient receiving low dose cyclophosphamide for treatment of rheumatoid arthritis.
    Ansher AF; Melton JW; Sliwinski AJ
    Arthritis Rheum; 1983 Jun; 26(6):804-5. PubMed ID: 6860382
    [No Abstract]   [Full Text] [Related]  

  • 28. Bladder cancer following administration of cyclophosphamide.
    Durkee C; Benson R
    Urology; 1980 Aug; 16(2):145-8. PubMed ID: 6250267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute granulomatous tubulointerstitial nephritis caused by intravesical BCG.
    Kennedy SE; Shrikanth S; Charlesworth JA
    Nephrol Dial Transplant; 2006 May; 21(5):1427-9. PubMed ID: 16455675
    [No Abstract]   [Full Text] [Related]  

  • 30. Carcinoma of the bladder in a patient treated with cyclophosphamide for rheumatoid arthritis.
    Hansen SE
    Scand J Rheumatol; 1983; 12(2):73-4. PubMed ID: 6857176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic predisposition and cyclophosphamide treatment in a girl with bladder carcinoma?
    Kenet G; Mandel M; Mor Y; Toren A; Jonas P; Kende G; Rechavi G; Neumann Y
    Med Pediatr Oncol; 1995 Apr; 24(4):269-70. PubMed ID: 7700174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of low-dose versus high-dose cyclophosphamide in lupus nephritis: comment on the article by Houssiau et al.
    Block JA
    Arthritis Rheum; 2003 May; 48(5):1466; author reply 1466-7. PubMed ID: 12746929
    [No Abstract]   [Full Text] [Related]  

  • 33. [Case of sarcomatoid carcinoma of the urinary bladder].
    Hosokawa Y; Kuwada M; Kumamoto H; Hayashi Y; Fujimoto K; Hirao Y
    Hinyokika Kiyo; 2008 Aug; 54(8):561-3. PubMed ID: 18788448
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carcinoma of the urinary bladder in patients receiving cyclophosphamide.
    Manoharan A
    Aust N Z J Med; 1984 Aug; 14(4):507. PubMed ID: 6596066
    [No Abstract]   [Full Text] [Related]  

  • 35. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.
    Takada K; Arefayene M; Desta Z; Yarboro CH; Boumpas DT; Balow JE; Flockhart DA; Illei GG
    Arthritis Rheum; 2004 Jul; 50(7):2202-10. PubMed ID: 15248218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; Garrido Ed Ede R; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year followup.
    Sanderson KM; Cai J; Miranda G; Skinner DG; Stein JP
    J Urol; 2007 Jun; 177(6):2088-94. PubMed ID: 17509294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide.
    Knight A; Askling J; Granath F; Sparen P; Ekbom A
    Ann Rheum Dis; 2004 Oct; 63(10):1307-11. PubMed ID: 15130900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transitional cell carcinoma in the paediatric population: be aware of unusual aetiologies.
    Dowling CR; Reddihough D; Smith P; Webb N; McNeill R; Clouston D
    J Paediatr Child Health; 2007 Nov; 43(11):773-5. PubMed ID: 17924939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Uroepithelial carcinoma in association with cyclophosphamide ingestion.
    Fuchs EF; Kay R; Poole R; Barry JM; Pearse HD
    J Urol; 1981 Oct; 126(4):544-5. PubMed ID: 7288948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.